ev3, Inc. (EVVV)
By: Zacks Equity Research
October 23, 2009 | Comment(s): 0
Recommended this article (0)
ev3, Inc. (EVVV) benefits from the growing demand for minimally invasive treatment of vascular diseases and disorders. Vascular disease and its precursors affect over 90 million people in the United States and more than 1 billion people worldwide. Vascular disease is the leading cause of death in the world.
The company's broad product portfolio makes it well positioned for long-term growth. In addition, ev3's products are primarily life-sustaining, a hedge against the current economic turmoil. We rate the company's stock an Outperform with a target price of $13.
ev3, Inc. (EVVV) : FULL ANALYST REPORT
|
|
||||||||||||||||||
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
More Zacks Links
| Market Summary | May 22, 2012 22:22 pm ET |
Partner Center

Sponsored Links 
Loading Stories...
-1.67
0.64